Distribution of high-risk Human Papillomavirus genotypes in cervical specimen from women using real-time PCR (Abbott m2000), a retrospective analysis over five years at Centre Pasteur du Cameroun
This five-year retrospective study at the Centre Pasteur du Cameroun reveals a 19.6% prevalence of high-risk Human Papillomavirus among tested women, characterized by a predominance of non-16/18 genotypes and no significant association with age, highlighting the critical need for broad-spectrum screening and expanded vaccine coverage in the region.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cervical cancer is a disease that almost always begins with a specific viral infection. The culprit is a virus called human papillomavirus, or HPV. While there are many different types of this virus, only a handful are considered dangerous because they can cause cells in the cervix to change and eventually become cancerous. These dangerous types are known as high-risk HPV. For decades, scientists have known that two specific types, numbered 16 and 18, are responsible for the majority of these cancers around the world. Because of this, vaccines were created to protect against these two main types, and screening tests were designed to look for them specifically. However, the virus does not behave the same way everywhere. In different parts of the world, other dangerous types of the virus might be more common than the famous two. Understanding which types are circulating in a specific region is vital for doctors to choose the right vaccines and the right tests to save lives.
In a five-year study conducted at the Centre Pasteur du Cameroun, researchers set out to map exactly which high-risk types of HPV were present in women seeking care in Cameroon. They looked at the records of 897 women who had their cervical samples tested between 2021 and 2025. The laboratory used a sophisticated molecular tool, a machine that can detect the genetic material of the virus, to see if any of the fourteen known dangerous types were present. This machine could tell the difference between the two most famous types, 16 and 18, and a group of twelve other dangerous types, though it could not identify the specific number of each type within that second group.
The results revealed a picture that differs significantly from the global average. Out of the nearly 900 women tested, about one in five had a positive result for a high-risk HPV infection. While the presence of the virus was concerning, the specific types found were the most striking part of the story. The two types that usually dominate the conversation, 16 and 18, accounted for only about a quarter of the positive cases in this group. This included instances where they appeared alone or combined with other types. The vast majority of infections, three out of every four, were caused by the other twelve high-risk types that the machine grouped together. This means that in this population, the virus types that standard vaccines might not cover, or that older screening tests might miss, were the ones actually circulating.
The researchers also wondered if age played a role in which type of virus a woman might carry. It is a common question whether younger women or older women are more likely to have one specific type versus another. After carefully comparing the ages of the women with the types of virus they carried, the team found no clear link. The pattern of infection remained the same across all age groups, from young adults to those over fifty-five. The dominant presence of the "other" types did not change as the women got older. This suggests that in this setting, the specific mix of viruses is a constant feature of the local environment rather than something that shifts as women age.
These findings carry important weight for public health in Cameroon and similar regions. The study confirms that relying solely on tests that look only for types 16 and 18 would miss most of the dangerous infections in this population. It also highlights that while vaccines are a powerful tool, the current versions might not protect against the full range of threats present in this specific part of the world. The researchers conclude that to effectively fight cervical cancer here, medical systems need to keep using broad tests that can spot all the dangerous types, not just the famous two. Furthermore, as vaccination programs expand, it will be essential to keep watching the virus closely to see if the mix of types changes over time, ensuring that the tools used to protect women remain effective against the specific threats they face.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.